Journal of Thrombosis and Thrombolysis

, Volume 33, Issue 3, pp 246–257 | Cite as

Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy

  • Deepak VooraEmail author
  • Thomas L. Ortel
  • Joseph E. Lucas
  • Jen-Tsan Chi
  • Richard C. Becker
  • Geoffrey S. Ginsburg


To develop an integrated metric of non-COX-1-dependent platelet function (NCDPF) to measure the temporal response to aspirin in healthy volunteers and diabetics. NCDPF on aspirin demonstrates wide variability, despite suppression of COX-1. Although a variety of NCDPF assays are available, no standard exists and their reproducibility is not established. We administered 325 mg/day aspirin to two cohorts of volunteers (HV1, n = 52, and HV2, n = 96) and diabetics (DM, n = 74) and measured NCDPF using epinephrine, collagen, and ADP aggregometry and PFA100 (collagen/epi) before (Pre), after one dose (Post), and after several weeks (Final). COX-1 activity was assessed with arachidonic acid aggregometry (AAA). The primary outcome of the study, the platelet function score (PFS), was derived from a principal components analysis of NCDPF measures. The PFS strongly correlated with each measure of NCDPF in each cohort. After 2 or 4 weeks of daily aspirin the Final PFS strongly correlated (r > 0.7, P < 0.0001) and was higher (P < 0.01) than the Post PFS. The magnitude and direction of the change in PFS (Final–Post) in an individual subject was moderately inversely proportional to the Post PFS in HV1 (r = −0.45), HV2 (r = −0.54), DM (r = −0.68), P < 0.0001 for all. AAA remained suppressed during aspirin therapy. The PFS summarizes multiple measures of NCDPF. Despite suppression of COX-1 activity, NCDPF during aspirin therapy is predictably dynamic: those with heightened NCDPF continue to decline whereas those with low/normal NCDPF return to pre-aspirin levels over time.


Aspirin Platelets Light transmittance aggregometry PFA100 Principal components analysis 



This study was funded by institutional funds provided by the Duke Institute for Genome Sciences & Policy, a National Institutes of Health (NIH) T32 Training grant (5T32HL007101 to DV), a grant (5UL1RR024128) from the National Center for Research Resources (NCRR), a component of the NIH, and NIH Roadmap for Medical Research, a grant (5RC1GM091083 to GSG) from the National Institutes of General Medical Sciences, and a grant (5U01DD000014-06 to TLO) from the Centers for Disease Control and Prevention. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH.

Supplementary material

11239_2012_683_MOESM1_ESM.docx (47 kb)
Supplementary material 1 (DOCX 46 kb)


  1. 1.
    Soni A (2007) Aspirin use among the adult U.S. noninstitutionalized population, with and without indicators of heart disease, 2005. Accessed 11 January 2012
  2. 2.
    Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD (2007) Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 50(19):1822–1834. doi: 10.1016/j.jacc.2007.07.051 PubMedCrossRefGoogle Scholar
  3. 3.
    Yee DL, Sun CW, Bergeron AL, Dong JF, Bray PF (2005) Aggregometry detects platelet hyperreactivity in healthy individuals. Blood 106(8):2723–2729PubMedCrossRefGoogle Scholar
  4. 4.
    FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ II, Lawson JA, Brash AR (1983) Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 71(3):676–688PubMedCrossRefGoogle Scholar
  5. 5.
    Pulcinelli FM, Pignatelli P, Celestini A, Riondino S, Gazzaniga PP, Violi F (2004) Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol 43(6):979–984PubMedCrossRefGoogle Scholar
  6. 6.
    Perneby C, Wallen NH, Rooney C, Fitzgerald D, Hjemdahl P (2006) Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost 95(4):652–658PubMedGoogle Scholar
  7. 7.
    Faraday N, Yanek LR, Mathias R, Herrera-Galeano JE, Vaidya D, Moy TF, Fallin MD, Wilson AF, Bray PF, Becker LC, Becker DM (2007) Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 115(19):2490–2496PubMedCrossRefGoogle Scholar
  8. 8.
    Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, Gesheff T, Chaganti SK, Etherington A, Tantry US (2007) Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 115(25):3156–3164PubMedCrossRefGoogle Scholar
  9. 9.
    Frelinger AL III, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, Furman MI, Michelson AD (2009) Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 120(25):2586–2596. doi: 10.1161/circulationaha.109.900589 PubMedCrossRefGoogle Scholar
  10. 10.
    Born GV (1964) Strong inhibition by 2-chloroadenosine of the aggregation of blood platelets by adenosine diphosphate. Nature 202:95–96PubMedCrossRefGoogle Scholar
  11. 11.
    Mori TA, Vandongen R, Douglas AJ, McCulloch RK, Burke V (1992) Differential effect of aspirin on platelet aggregation in IDDM. Diabetes 41(3):261–266PubMedCrossRefGoogle Scholar
  12. 12.
    Schwartz KA, Schwartz DE, Pittsley RA, Mantz SL, Ens G, Sami A, Davis JM (2002) A new method for measuring inhibition of platelet function by nonsteroidal antiinflammatory drugs. J Lab Clin Med 139(4):227–233PubMedCrossRefGoogle Scholar
  13. 13.
    Becker DM, Segal J, Vaidya D, Yanek LR, Herrera-Galeano JE, Bray PF, Moy TF, Becker LC, Faraday N (2006) Sex differences in platelet reactivity and response to low-dose aspirin therapy. Jama 295(12):1420–1427PubMedCrossRefGoogle Scholar
  14. 14.
    Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A, Pettinella C, Recchiuti A, Ferrante E, Ciabattoni G, Davi G, Patrono C (2009) Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin “Resistance”. J Am Coll Cardiol 53(8):667–677PubMedCrossRefGoogle Scholar
  15. 15.
    Ortel TL, James AH, Thames EH, Moore KD, Greenberg CS (2000) Assessment of primary hemostasis by PFA-100 analysis in a tertiary care center. Thromb Haemost 84(1):93–97PubMedGoogle Scholar
  16. 16.
    Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W (2000) Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 83(2):316–321PubMedGoogle Scholar
  17. 17.
    Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, Satta MA, Peskar BA (1980) Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 17(3–4):317–327PubMedCrossRefGoogle Scholar
  18. 18.
    Roberts MS, McLeod LJ, Cossum PA, Vial JH (1984) Inhibition of platelet function by a controlled release acetylsalicylic acid formulation—single and chronic dosing studies. Eur J Clin Pharmacol 27(1):67–74PubMedGoogle Scholar
  19. 19.
    Frelinger AL III, Furman MI, Linden MD, Li Y, Fox ML, Barnard MR, Michelson AD (2006) Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 113(25):2888–2896PubMedCrossRefGoogle Scholar
  20. 20.
    Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38(8):904–909PubMedCrossRefGoogle Scholar
  21. 21.
    Landgrebe J, Wurst W, Welzl G (2002) Permutation-validated principal components analysis of microarray data. Genome Biol 3(4):research0019.1–research0019.11CrossRefGoogle Scholar
  22. 22.
    Shah SH, Hauser ER, Bain JR, Muehlbauer MJ, Haynes C, Stevens RD, Wenner BR, Dowdy ZE, Granger CB, Ginsburg GS, Newgard CB, Kraus WE (2009) High heritability of metabolomic profiles in families burdened with premature cardiovascular disease. Mol Syst Biol 5:258PubMedCrossRefGoogle Scholar
  23. 23.
    Yee DL, Bergeron AL, Sun CW, Dong JF, Bray PF (2006) Platelet hyperreactivity generalizes to multiple forms of stimulation. J Thromb Haemost 4(9):2043–2050PubMedCrossRefGoogle Scholar
  24. 24.
    Williams MS, Weiss EJ, Sabatine MS, Simon DI, Bahou WF, Becker LC, Parise LV, Dauerman HL, French PA, Smyth SS, Becker RC (2010) Genetic regulation of platelet receptor expression and function: application in clinical practice and drug development. Arterioscl Thromb Vasc Biol 30(12):2372–2384. doi: 10.1161/ATVBAHA.110.218131 PubMedCrossRefGoogle Scholar
  25. 25.
    Ohmori T, Yatomi Y, Nonaka T, Kobayashi Y, Madoiwa S, Mimuro J, Ozaki Y, Sakata Y (2006) Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost 4(6):1271–1278. doi: 10.1111/j.1538-7836.2006.01958.x PubMedCrossRefGoogle Scholar
  26. 26.
    Zufferey A, Reny JL, Combescure C, de Moerloose P, Sanchez JC, Fontana P (2011) Platelet reactivity is a stable and global phenomenon in aspirin-treated cardiovascular patients. Thromb Haemost 106(3):466–474. doi: 10.1160/TH11-04-0226 PubMedCrossRefGoogle Scholar
  27. 27.
    Mathias R, Kim Y, Sung H, Yanek L, Mantese V, Hererra-Galeano E, Ruczinski I, Wilson A, Faraday N, Becker L, Becker D (2010) A combined genome-wide linkage and association approach to find susceptibility loci for platelet function phenotypes in European American and African American families with coronary artery disease. BMC Med Genomics 3(1):22PubMedCrossRefGoogle Scholar
  28. 28.
    Johnson AD, Yanek LR, Chen M-H, Faraday N, Larson MG, Tofler G, Lin SJ, Kraja AT, Province MA, Yang Q, Becker DM, O’Donnell CJ, Becker LC (2010) Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists. Nat Genet 42(7):608–613. Google Scholar
  29. 29.
    Cuisset T, Frere C, Quilici J, Gaborit B, Bali L, Poyet R, Faille D, Morange PE, Alessi M-C, Bonnet J-L (2009) Aspirin noncompliance is the major cause of “aspirin resistance” in patients undergoing coronary stenting. Am Heart J 157(5):889–893PubMedCrossRefGoogle Scholar
  30. 30.
    Patrono C, Rocca B (2007) Drug insight: aspirin resistance—fact or fashion? Nature clinical practice cardiovascular medicine 4(1):42–50. doi: 10.1038/ncpcardio0728 PubMedCrossRefGoogle Scholar
  31. 31.
    Angiolillo DJ, Suryadevara S (2009) Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus. Best Pract Res Clin Endocrinol Metab 23(3):375–388PubMedCrossRefGoogle Scholar
  32. 32.
    Hayward CPM, Harrison P, Cattaneo M, Ortel TL, Rao AK, The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2006) Platelet function analyzer (PFA)-100® closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 4(2):312–319PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Deepak Voora
    • 1
    Email author
  • Thomas L. Ortel
    • 1
  • Joseph E. Lucas
    • 1
  • Jen-Tsan Chi
    • 1
  • Richard C. Becker
    • 1
  • Geoffrey S. Ginsburg
    • 1
  1. 1.Institute for Genome Sciences and PolicyDuke UniversityDurhamUSA

Personalised recommendations